Funding Requirement for SCI 2018-2021

Summary

The budget requirement for SCI has been presented across 3 financial years; 2018-2019, 2019-2020 and 2020-2021 as per the UK financial year which SCI adopts.

In line with the strategic vision of SCI to eliminate schistosomiasis (SCH) in sub-Saharan Africa, our ideal funding scenario prioritises:

- Ensuring ongoing support for SCH and STH interventions in existing countries within SCI’s portfolio
- Expanding treatment to all at-risk populations to achieve elimination goals
- Enhanced Monitoring and Evaluation activities to strengthen programme interventions and improve coverage.

At higher funding revenues, we would expand to include other countries within the African region who do not have a current committed funding source for treatment of SCH and STH.

Assumptions: Spreadsheet: GiveWell Funding Scenarios 2018 – 2021

This is a projection of where countries might be in the WHO ‘control of morbidity’ and ‘elimination of public health problem’ phases over the next 3 years, also taking into account periods of reassessment where morbidity targets may have been met.

<table>
<thead>
<tr>
<th>WHO treatment strategy adopted</th>
<th>Target</th>
<th>Cost per Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control of morbidity</td>
<td>100% of WHO Population requiring PC for SCH annually</td>
<td>£0.18</td>
</tr>
<tr>
<td>Reassessment after 5 rounds of treatment</td>
<td>50-100% of WHO Population requiring PC for SCH annually</td>
<td>£0.18 - £0.27</td>
</tr>
<tr>
<td>Elimination as a PHP</td>
<td>50% of WHO Population requiring PC for SCH annually</td>
<td>£0.27</td>
</tr>
</tbody>
</table>

Each country has been assigned a programme phase and calculations made accordingly to estimate the associated MDA costs.
Schistosomiasis Control Initiative (SCI),
Department of Infectious Disease Epidemiology, School of Public Health,
Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK
T: +44 (0)20 7594 3287    F: +44 (0)20 7262 8140    W: www.schisto.org

| **The MoH is working on developing a plan for treatments by funder therefore SCI proportion is expecting to reduce according to MoH requirements. This will be updated when available.** |
| **Nigeria Target population** | Consolidates the 5 states in which SCI funding is leverage to reach full coverage of all endemic LGAs and including a 6\(^{th}\) state, Osun, over the 3 year period. |
| **Additional PZQ required** | Assumes all PZQ for SAC will be leveraged from the WHO donation programme which is scaling to 250 million tablets per year. Additional PZQ is therefore required to be procured for the remaining target population at 3 tablets per person. |
| **Cost per tablet** | Assumes the 2017 average cost per tablet purchased remains stable at £0.08 |

**Expansion Scenario 2018-2021 Tab – should higher revenue be received**

- **Cost per treatment**
  - Assumes a higher initial cost per treatment in the first year of implementation at £0.27

- **New Programme countries**
  - Assumes control of morbidity only during the start-up phase targeting coverage in SAC only

**Reduced Scenario 2018-2021 Tab – should reduced revenue be received**

- **Assumptions as per existing programmes**
- **Treatment beyond SAC in countries only where there is a precedent in existing programmes**
- **No additional PZQ procurement; leveraged PZQ donation and purchased PZQ through DFID only**